




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



A systematic review on recent trends in transmission, diagnosis, prevention and imaging features of COVID-19

S. Manigandan^{a,b,c}, Ming-Tsang Wu^{a,d,e,f}, Vinoth Kumar Ponnusamy^{a,b,g,h,*},
Vinay B. Raghavendraⁱ, Arivalagan Pugazhendhi^j, Kathirvel Brindhadevi^{k,*}

^a Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan

^b Department of Medicinal and Applied Chemistry, Kaohsiung Medical University, Kaohsiung 807, Taiwan

^c Faculty of Science, Sathyabama Institute of Science and Technology, Chennai 600 119, India

^d Department of Public Health, College of Health Sciences, Kaohsiung Medical University, Kaohsiung Taiwan

^e Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung Taiwan

^f Department of Family Medicine, Kaohsiung Medical University Hospital, Kaohsiung Taiwan

^g Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Taiwan

^h Department of Chemistry, National Sun Yat-sen University, Kaohsiung Taiwan

ⁱ Teresian Research Foundation, Siddarthanagar, Mysore 570011, India

^j Innovative Green Product Synthesis and Renewable Environment Development Research Group, Faculty of Environment and Labour Safety, Ton Duc Thang University, Ho Chi Minh City, Viet Nam

^k Institute of Research and Development, Duy Tan University, Da Nang 550000, Viet Nam

ARTICLE INFO

Keywords:

Coronaviruses
COVID-19
SARS-CoV-2
Transmission
Reproduction number
Pathogenesis

ABSTRACT

As the new cases of COVID-19 are growing every daysince January 2020, the major way to control the spread washrough early diagnosis. Prevention and early diagnosis are the key strategies followed by most countries. This study presents the perspective of different modes of transmission of coronavirus,especially during clinical practices and among the pediatrics. Further, the diagnostic methods and the advancement of the computerized tomography have been discussed. Droplets, aerosol, and close contact are the significant factors to transfer the infection to the suspect. This study predicts the possible transmission of the virus through medical practices such as ophthalmology, dental, and endoscopy procedures. With regard to pediatric transmission, as of now, only a few child fatalities had been reported. Children usually respond to the respiratory virus; however, COVID-19 response is on the contrary. The possibility of getting infected is minimal for the newborn. There has been no asymptomatic spread in children until now. Moreover, breastfeeding would not transmit COVID-19, which is encouraging hygiene news for the pediatric. In addition, the current diagnostic methods for COVID-19 including Immunoglobulin M (IgM) and Immunoglobulin G (IgG) and chest computed tomography (CT) scan, reverse transcription-polymerase chain reaction (RT-PCR) and immunochromatographic fluorescence assay, are also discussed in detail. The introduction of artificial intelligence and deep learning algorithms has the ability to diagnose COVID-19 in precise. However, the developments of a potential technology for the identification of the infection, such as a drone with thermal screening without human intervention, need to be encouraged.

1. Introduction

Coronavirus disease (COVID-19) is initially identified as a pneumonia virus in Wuhan, and it is named as SARS-CoV-2 by the World Health Organization (WHO) on 12th Jan 2020. This disease originated from a local seafood market in Huanan, Wuhan city, China [1]. The

common symptoms of early infections are fever, cough, and other respiratory issues. Some patients have not reported any symptoms. Among the infected patient, 68 % reported dry cough and the 33 % observed with wet cough (mucus production). Cough is a major transmission route of CoV-2. To avoid the cough the infected patients were treated with lidocaine during intubation and extubation. Lidocaine reduces the

* Corresponding authors.

E-mail addresses: kumar@kmu.edu.tw (V.K. Ponnusamy), arivalagan.pugazhendhi@tdtu.edu.vn (A. Pugazhendhi), kathirvelbrindhadevi@duytan.edu.vn (K. Brindhadevi).

<https://doi.org/10.1016/j.procbio.2020.08.016>

Received 23 May 2020; Received in revised form 4 August 2020; Accepted 19 August 2020

Available online 20 August 2020

1359-5113/© 2020 Elsevier Ltd. All rights reserved.

cough without major side effects [52]. In addition, 82.1 % of patients had lymphopenia, and 33.7 % had leukopenia. As the infection increases, the infected patient faces severe respiratory syndrome, lung issues, and kidney failure in some cases. Clinical observations stated no response for treatment with conventional antibiotics. The patients still lost their blood cells and had an uncontrollable body temperature. COVID-19 looks similar to the severe acute respiratory syndrome-related coronavirus (SARS-CoV) that originated from bats [2,3]. However, few samples revealed that the spike protein content of SARS-CoV-2 is not a bat beta-coronavirus nor the pangolin beta-coronavirus [4,5]. Further, no animal virus looked the same as CoV-2. Besides, the mutations in the spike protein make the CoV-2 bind with the human angiotensin-converting enzyme 2 (ACE2). The progenitor of CoV-2 jumped to humans without being detected, and it was transmitted rapidly from human to human. Similar to CoV-1, CoV-2 acquired receptor-binding domain (RBD) mutations during transmission in the cell, where the study revealed that CoV-2 is not a purposefully modified virus. However, at the moment, it cannot be proved or disproved with the available data [6,7].

CoV-2 is a Ribonucleic acid (RNA) virus, which can infect animals and humans. The infection with coronavirus leads to respiratory, gastrointestinal, and neurologic syndromes [8]. It has been believed that wild animals and bats are the natural hosts. Wuhan reported that the patients are suffering from viral pneumonia fever in the city starting from December 2019. It was identified as a CoV virus and later named as SARS-CoV-2. CoV-2 virus consists of a structured protein such as spike (S), membrane (M), envelope (E), hemagglutinin esterase (HE), and nucleocapsid (N). Electron microscopy revealed that compared to other proteins, the content of M is higher. Thus, the M protein determines the shape of COVID-19 [9,10].

Further, the coronavirus is zoonotic in origin [11]. Hence, it can evolve into a strain to infect humans. The primary symptoms are fever (88 %), fatigue (38 %), dry cough (68 %), sore throat (15 %), sputum production (33 %), muscle pain (15 %) and respiratory problems (19 %) [12]. As of now (January 10 to March 30, 2020), there were 752,263 reported COVID-19 cases and 36,204 deaths around the world as per the record of worldometers with the mortality rate of 15 %. The mortality rates were high in April 2020. As the treatment procedure was aggravated, the mortality rates were reduced significantly. The current mortality is 10 %, which is a positive note. However, the report on new cases is growing. In the last few months (April 2020- June 2020), the report of fresh cases of COVID-19 increased by 54 %, which needs extensive attention. As of 10 June 2020, the total cases were approximately 7,451,900, with reported deaths of 418,891. Fig. 1 indicates the total number of COVID-19 cases identified in the major countries.




Fig. 1. Total number of COVID-19 cases identified in the major countries between June 1~ July 07, 2020 [European CDC].

2. Transmission of COVID-19

The transmission takes place mainly through human to human during intimate contact with each other. In the early period, it was reported that coronavirus affected 72 % of resident people, and 31 % had a travel history to Wuhan [13]. Recent researches have pointed out that human proximity and social interaction increase the transmission of the virus. Finding the transmission link is very tedious. Thus, mathematical modeling patterns are applied to predict infectious transmission. Although there are several methods to predict the rate of spread, the uncertainty is high [14,15]. Among the several rates of transmission, the droplets are the primary sources (Fig. 2). Picking the contaminated surfaces and touching face increases the risk of getting infected. The recent spread of infection through stool has been confirmed [16]. The latest investigation reveals the possibility of transmission through the ocular surface [17]. Studies showed the impact of handwashing and transmission of the virus after hand sanitizing. They identified that washing hands at least 5 times per day would reduce the overall risk of infection [Incidence rate ratios (IRR) = 0.35, P = 0.02]. Further, washing hands after cough or sneeze minimize the risk of transmission via household objects [IRR = 3.35 & P = 0.02] [18]. The importance of the mask and the social distancing were discussed in detail. In general the particles (60–100 μm) emitted by the infected person fall to the ground within 6 feet. However, in some rare cases stimulated cough and sneeze droplets (> 0.1 mm) of the person can travel more than 12 feet. Since the average person aerosol transmission occurs between 4.5–6 feet, the social distance of 6 feet rule has been strictly followed. Besides, the social distancing rules differ from countries to countries based on the rules imposed by the regional authorities guidelines. For instance, Australia follows 5 feet whereas the Denmark, France and Lithuania follow 3 feet rules. Notable study concluded the 13 % of the risk of getting infected takes place within 1 m. Beyond 1 m, the risk rate drastically reduced to 3 %. Further, for every increase in 3 feet reduces the risk by half.

To avoid transmission of the virus wearing mask and the social distancing are the effective tool. Based on the current evidence the proper mask reduces the transmission of droplets on both clinical and laboratory environment. Despite the several types of mask, N95 offers higher protection followed by surgical mask against COVID-19. Due to the limitation of N95, the non-health care people are recommended to use handmade cloth mask with adequate social distancing guidelines and recommendations. A notable article made a natural study on the mandate face mask and the growth rate of infection. Wearing the mask reduces the growth rate of COVID-19, which became obvious. Decline in the growth rate were reported after the US state government mandates the face mask. For instance after 5th date of mandate face mask the growth rate dropped by 1.1 % and it is increased to 2 % after couple of weeks. From this significance finding, role of face mask and social distancing was apparent [51].

Identifications of the infection at the early stages are possible by developing superior technology. For instance, the drone with a thermal camera can detect the infected person without any human intervention. Further, it can be useful to identify the person not wearing mask through artificial intelligence technology. Few notable works reveal the reproduction number (R_0) can be changed from 1.5–6.49 based geographic locations. Further, the key studies reveal the R_0 of CoV-2 to be 3.28, which is higher than the early prediction by the WHO. Further, based on the current reproduction rate, the median is 2.79, and the interquartile range (IQR) was 1.16 [1]. Several guidelines have been proposed for both medical personnel and infected patients to ensure high safety such as,

For medical personnel,

- The medical staff treating the patient should be isolated
- Their routine activities must be monitored




Fig. 2. Transmission of COVID-19 to the susceptible individual.

- If they witness any problems such as fever, cold, and cough, they need to be quarantined
- The team officials must check whether the medical personnel are following the preventive measures.

Recent studies showed that CoV-2 could live in the air for several hours, and it can remain intact on the surface for more than 2–3 days. Further, the findings observed that the virus could live up to 4 h in copper and 2–3 days in steel. Moreover, the virus stays on plastic longer than any other host. However, there is no evidence of cloth exposure still [19]. Meanwhile, they also observed that the virus could spread through droplets in air medium, by human contact and surface contact. Some myths indicated that COVID-19 could not live in hot temperatures. However, there is no adequate proof of the same. Thus, isolating infected patients is very crucial. As per the WHO situation report 64, European regions and northern America have been confirmed with the highest number of cases [4]. This denotes the crucial role of temperature on transmission. The patients must be identified before they transmit the disease. It can be made possible by the screening criteria.

Some preliminary countermeasures are,

- Finding the history of the travel and quarantine
- Monitoring the temperature of the people
- Observing the movement of people who are in-home quarantine.
- Alerting the society by pasting the warning symbols on the respective walls of home quarantine person
- Identifying the premature sickness (If the patients are infected, they are treated with oxygen therapy, intravenous immunoglobulin, antiviral therapy, and empirical antimicrobial therapy).

From the previous lessons learned through the management of several diseases, prevention is the best cure to fight against this new novel virus to reduce the mortality rate. Four key features can avoid fatalities, such as prevention, response, transmission, and treatment.

2.1. Transmission of COVID-19 through eyes

Sun et al. reported the transmission of novel coronavirus through the eyes. The role of the eye in transmitting the SARS-CoV and COVID-19 is scarce. Nevertheless, the entry of CoV is tested through the exposure of tears and conjunctival secretions from infected patients. Further, the viral transmissions during the practice of ophthalmic diagnosis are

possible. Thus, medical personnel are strictly advised to maintain hand hygiene and personnel protection [20]. As per the previous infections of SARS-CoV, exposure of the virus to ultraviolet irradiation and heating can control infection. Further, sterilization at 56 °C for 30 min with lipid solvents can make the ophthalmic instrument safe from transmitting.

2.2. Transmission of COVID-19 through dental procedures

The possibility of transmission through dental practice is higher owing to close communication, exposure of saliva, blood, and body fluids. Thus, the dentist has to be very cautious being injected. To prevent transmission through dental practices, some essential countermeasures are necessary.

There are different types of transmission, such as airborne, contact spread, and surface spread. Hence, there must be precautions before handling patients [21]. The crucial key points are

- Hand hygiene
- Use of personal protective measures
- Mouth rinse before dental procedures
- Knowing the travel history of the patient
- Rubber dam isolation
- Antiretraction hand piece
- Disinfection of the clinical settings
- Handling the medical wastes
- By managing the above things, the spread through the dentistry can be avoided.

2.3. Transmission of COVID-19 through endoscopy

Endoscopy health care personnel will mostly not be working with COVID-19 patients. However, it is essential to know the critical things to stop the transmission during endoscopy treatments in the case of COVID-19 patients. During the treatment procedure, the distance between the patient and medical personnel is very short, which risks the spread of infection. Every patient undergoing the endoscopic treatment procedures, including 14 days track record examination such as travel history, body temperature, and other symptoms need to be checked. By doing the above method, the risk factor can be reduced. Further, the patient having any contact with the CoV-2 person or asymptomatic COVID-19 person will have a high risk of executing the endoscopy procedure by the doctors [22]. On the contrary, wearing personal protective

equipment's such as mask, gloves, goggles, gowns, shields and other respiratory equipment's are essential, which must be followed during this outbreak, especially and also the rapid testing method of COVID-19 can be used to evaluate the infection prior to endoscopy. The key ways of possible transmission during endoscopy are human to human, droplets, air, and body fluids [23].

If any of the patients were found to be suffering from CoV-2 after the procedure, the entire room, including all the equipments must be sterilized and sanitized to avoid potential transmission.

2.4. Transmission of COVID-19 in pregnant women and infants

The incubation periods of COVID-19 are approximately 14 days [24]. The first child case was reported in Shenzhen. As of now, there are more than 230 children being affected by the coronavirus with no fatality [25]. Similar to SARS, there is no mortality for COVID-19. However, the transmission of disease from neonates and children are possible. Thus, wearing protective equipments such as hats, gloves, suits, goggles, and mask are essential [26,27]. Chen et al. reported a clinical course of four live-born infants whose mother infected with the virus at trimester and witnessed fever, cough, headache at the time of admission in the hospital. After the necessary test, it is observed lymphocytes were below the normal range for all patients. After performing CT, there are some abnormalities seen among all. Three patients underwent caesarean, and one patient with vaginal delivery. After the full-term birth of infants, they are isolated. A few days later, all mothers successfully recovered from COVID-19 infection. Although the mother possesses positive COVID-19 during pregnancy, their infant tested negative. So there is no transmission from mother to infant [28].

In another notable study, Liu et al. studied the reason for pregnant women being more susceptible to COVID-19. They reported no vertical transmission of the virus. Further, they found the virus to have the capacity to alter the immune response [29,30]. Hung et al. studied clinical and vertical transmission in nine pregnant women for novel pneumonia fever (COVID-19). Among the nine, seven suffered fever, including cough, sore throat, and malaise. Further, five patients experienced lymphopenia. The delivery of the newborn was successful. There was no vertical transmission, and breast milk samples tested negative for the virus [31]. This denoted that breastfeeding can be done to the infants, even the mother is infected.

3. Diagnostic methods and procedures

COVID-19 can be detected using various diagnostic procedures such as chest CT scan, acid detection, epidemiological history, and clinical treatment. Since COVID-19 is highly contagious, finding a rapid and reliable diagnosis technique is significant. Although the origin of the virus took place in Wuhan, now under control there due to the effective utilization of diagnostic tests to identify the individual before the reproduction rates of infection were increased [32]. At the time of origin, the test procedures are different when compared to the latest clinical practices. For instance, the patients are subjected to a CT scan to find the infection. However, nowadays, the rapid test kits are used to predict the infection though uncertainty is a problem.

IgM and IgG is a simple technique performed to diagnosis the infected person. The test performed on 57 individuals. On comparing, IgG reported 72.7 % of the detection rate. Besides, the nucleic acid test report 87.5 %. Moreover, high-sensitivity C-reactive protein (hs-CRP) nucleic acid negative group observed higher test results compared to the positive group [33,34]. To sum up, the use of IgM and IgG over nucleic acid detection is highly recommended. Furthermore, a combination of all these to predict COVID-19 leads to high reliability and precision. Zhang et al. diagnosed the presence of COVID-19 by identifying the presence of the spike protein. They evaluated six recombinant nucleocapsid and spike proteins using IgM and IgG. They found that rs1 and rs-receptor binding domain-mFc are highly suitable to diagnose

theHCoV-19. In the same way, gold immunochromatography assay (GICA) can be used to identify the antibodies [34,35].

Unlike the above method, the chest CT is widely used to find the infected person through diagnostic imaging. The CT is performed only on the person who has been infected severely. In many positive patients, pulmonary consolidation is observed, and based on that, the infected patients are quarantined. In addition, few patients were observed with a decrease in WBC and lymphocytes. The effects of infection in Hubei patients were compared with those from other countries. This comparative determination has aided in correlating the transmission of the virus from one geographic location to another. All patients, irrespective of their origin, suffered from fever, cough, and other respiratory issues. Likewise, the decrease in WBC and lymphocyte count was also seen [36]. In traditional clinical procedures, X-ray imaging is performed to identify pulmonary diseases. However, in the case of COVID-19, using X-ray will not help due to the poor imaging characteristics, as shown in Table 1. Thus, CT is used to identify the infected person. Generally, the uncertainty in determination exists owing to false-negative ground-glass opacification (GGO) detection. Moreover, the imaging differs from case to case based on age, infection seriousness, and health status. To identify the infection, a comprehensive diagnosis must be made using distribution pattern, quantity and range, density, shape, interface, internal features of the lesion and adjacent structural changes, CT staging, quantitative CT, and artificial intelligence (AI). The determination of CoV-2 using CT is not very clear. Furthermore, using CT on children is not specific [37,38]. Thus, advanced computer-aided CT and AI are required urgently for screening patients and conducting virus surveillance. Further, analyzing the CT images by AI using deep learning reduces the uncertainty in the confirmation of the positive new case. Few notable works incorporated the neuro-network through a deep learning model, which has achieved 82 % accuracy on findings. Song et al. proposed a framework to predict COVID-19 with minimum time using AI technology engines. The designed framework was made of simple Smartphone sensor measurements. The designed framework was comprised of a series of layers, such as input, measurement, sensing, computing, and predicting layers. The implementation of the proposed AI increased the mobility of diagnosis. The reliability was higher since the framework used multiple readings to diagnose. Another reliable method is deep learning. Deep learning was proposed based on the CT diagnosis system to detect patients with COVID-19 using radiograph imaging. The model was built based on 88 patients' CT images. The DREnet architecture used ground-glass opacity in CT images to assist doctors in determining the infected persons [39].

Another technique involves the use of real-time fluorescent RT-PCR to identify the virus [40]. Figs. 3 and 4 shows the diagnostic techniques to determine the infection using PCR kits. Initially, the duration of the test took two minimum days. After the upgrade, the reports are available within 6 h. Based on the accumulated experience, the PCR is replaced with a CT scan for the confirmed person. Based on the early prediction, the patient would receive special attention to fight COVID-19 [41]. Despite the above, a determination of the CoV-2 is possible by using immunochromatographic fluorescence assay. The fluorescence would be applied to the samples to detect the presence of the nucleocapsid protein of CoV-2. 239 patients were diagnosed with nucleocapsid

Table 1
Comparison of diagnostic imaging technique for COVID-19.

Type of diagnostic imaging		
X-radiation	Computed Tomography	Ultrasound
<ul style="list-style-type: none"> GGO (No sensitive) 	<ul style="list-style-type: none"> GGO Consolidation with air bronchogram Crazing paving (Superimposed inter and intralobular septal thickening) 	<ul style="list-style-type: none"> Pleural line thickening (Increase in B-line) Consolidation with air bronchogram




Fig. 3. Diagnostic procedures of COVID-19.




Fig. 4. Test sample preparation for the analysis of COVID-19 for reverse transcription polymerase chain reaction (RT-PCR).

protein using nucleic acid test. All the patients underwent the acid test repeatedly for three times. On the whole, 208 patients tested positive for nucleic acid and 31 negatives for nucleic acid. Besides, the nucleic acid test is unstable, and the uncertainties in the test are high. Thus, the double-blind evaluation of the test is mandatory [42].

3.1. Comparative analysis of CT and RT-PCR

The CT diagnosis employed to the COVID-19 positive patients based on the RT-PCR results. CT imaging is done based on a 4-day interval to monitor the function of the respiratory syndrome. CT scans are usually conducted on a single respiratory phase. To reduce the uncertainties, the patients are advised to hold breath during CT imaging [40,41]. The distribution of the abnormalities are recorded and evaluated by the digital database and the radiologist. The patients are evaluated based on the ground glass opacity, crazy paving, and consolidation. A notable studied derived CT scan observations based on the seriousness of infections. All the patients were hospitalized and discharged after recovery with the mean days of 18. Based on imaging, the infection can be categorized into 4 stages. Further, the CT scan classified the different lobes such as left upper, left lower, right middle, and right lower. During stage 1, the maximum numbers of patients were observed with GGO (75 %), lesions in single lobe (42 %), and Consolidation (42 %). At stage II, consolidation (47 %), GGO (82 %), Crazy paving (53 %), multilobe (77 %), and peripheral lesion (59 %). Followed by at stage III, peripheral (70 %), bilateral multilobe (86 %), GGO (71 %), and consolidation (91 %). At stage IV, peripheral (70 %), bilateral multilobe (80 %), GGO (65 %), consolidation (75 %), and crazy paving pattern (0 %) [38]. As the patients getting cured, the GGO is decreased and the null observation for crazy paving patterns. From the above distribution frequency, it is evident COVID-19 can be diagnosed using GGO, consolidation, and crazy paving pattern. Further, the distribution of pulmonary lesion and the involvement of lesions also helped to detect the COVID-19 with the least precision since many patients were not observed with lesions [41].

Some studies revealed the effectiveness of PCR on CT. To understand this, comparative analysis between both is mandatory. A case report had been generated for 1014 confirmed cases in China. Based on the test data of 1014 suspected cases, the comparison of RT-PCR and CT is prepared. Nevertheless, the time interval between the RT-PCR and CT is approximately 5 days. Ai et al. reported a basic comparison of CT and PCR for 167 patients in China. Based on the comparison they revealed, 155 patients were confirmed with COVID-19 infection by testing using both. On the contrary, 12 patients were tested with false results in PCR compared to CT [42,43]. Further, the usage of PCR led to false negatives owing to insufficient viral material and laboratory errors. Yet again, immature nucleic acid, insufficient viral load, improper clinical sampling, low detection rate, and manufacturing defects were the other possibilities of errors in RT-PCR. By concluding all, CT is considered as more reliable for comprehensive evaluation and screening. Another study performed a statistical analysis using SPSS version 21.0. 95 % of the confidence interval was observed by the Wilson score method. Some patients with negative RT-PCR were confirmed with the infection by CT scans [43,44]. Thus, CT is preferred over RT-PCR when the patients carry clinical symptoms such as shortness of breath, cold, fever, and diarrhea. On the other end, the correlation between RT-PCR and CT was done to make sure the infected patients after complete recovery.

In summary, COVID-19 can be identified with higher precision using CT than RT-PCR. Further, the diagnosis of infection is possible by identifying the GGO and consolidation along the subpleural area of the lung. Identification of infected patients using CT can be more efficient to enable the prevention of infection transmission.

3.2. Molecular assays for COVID-19 diagnosis

Recently, there are various molecular assay methods that can detect 2019-nCoV, and some are under research and development to increase

the testing feasibility to identify COVID-19 patients. Few assay methods selectively detect the novel CoV, and some assays also detect other CoV strains (e.g., SARS-CoV), which are genetically identical. Most countries shared their molecular assay protocols (Table 2). The list is not exhaustive and is being updated based on the current research. United States of America and China, Center for disease control and prevention (CDC) are extensively working on the assays by targeting the genes such as open reading frame 1ab (ORF1ab), RNA dependent RNA polymerase (RdRp) and nonstructural protein 14 (nsp14) for the detection of CoV-2 with high accuracy [45,47].

Recently, Abbott came up with ID NOW™ COVID-19, which can deliver the results in 5 min targeting the RdRp gene. The sampling types are throat, nasal, oropharyngeal swabs, and nasopharyngeal. The company decided to make a large batch production, which helps to diagnose the COVID-19 at a very early stage. This will create a critical change in the current scenario (Table 3).

4. Outlook of clinical procedures and treatment

Wei et al. made a study on the clinical characteristics of CoV-2 in China. More than a thousand patient data were extracted. The majority of the infected persons were treated with antibiotic therapy (58 %), oseltamivir (36 %), oxygen therapy (41.3 %), and mechanical ventilation (6.1 %). Mechanical ventilation is used in patients who are in critical condition. Among all the patients, 204 patients are hospitalized for a minimum of 12 days [13].

Han et al. reported the clinical treatment procedure for a 47-year-old man in Wuwei. The patient tested positive, and the test results indicated that the patient suffered from decreased lymphocytes, increased C-reactive protein, high fibrinogen, and elevated lactic dehydrogenase [45]. Further, CT reported a multiple patchy high-density shadow, similar to other patients reported in the notable literature [46]. To handle the respiratory issue, oxygen inhalation therapy was used. In addition, rehydration therapy was performed. Blood glucose and blood pressure were closely monitored. In addition, the patient was treated with lopinavir and ritonavir tablets. After a day's treatment, the patient faced shortness in breath and chest tightness, occasionally. On the following day, methylprednisolone was advised for 5 days. The patient was discharged on day 10 without any symptoms. The detailed procedure on medication is available in the literature [48,49]. Although the treatment was continuous, the patient's body temperature, blood pressure, and respiratory rate were on fluctuations [50].

Based on the response of the infected patients, 15 drugs were initially identified as the potential break through for the treatment of the COVID-19 are chloroquine-hydroxychloroquine, lopinavir-ritonavir, nafamostat-camostat, famotidine, umifenovir, nitazoxanide, ivermectin, corticosteroids, tocilizumab-sarilumab, bevacizumab and Fluvoxamine [53]. Besides, based on the recent reports dexamethasone and remdesivir drugs are widely considered as the life saving drug. Based on the study on 1063 patients it was convinced that, remdesivir performed significantly in reducing the symptoms and the recovery time of the adults with the COVID-19 infection [54]. However use of the remdesivir

Table 2

Summary of available molecular assays protocols for COVID-19 diagnosis as per WHO [43–49].

Gene targets	Institute	Country
ORF1ab and N	China CDC	China
RdRp, E, N	Charité	Germany
ORF1b-nsp14, N	University of Hong Kong	Hong Kong
Pancorona and multiple targets, Spike protein	National Institute of Infectious Diseases, Department of Virology III	Japan
N	National Institute of Health	Thailand
Three targets in N gene	United States CDC	US
Two targets in RdRp	Institut Pasteur, Paris	France

Table 3

Major vaccine candidates in preclinical stages of development and research [56].

Candidate	Sponsor/Firm	Trial Phase
Inactivated vaccine	Wuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)	Phase 3
CoronaVac	Sinovac	Phase 3
Bacillus Calmette-Guerin (BCG) live-attenuated vaccine	University of Melbourne and Murdoch Children's Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General Hospital	Phase 2/3
AZD1222	The University of Oxford; AstraZeneca; IQVIA	Phase 2/3
mRNA-1273	Moderna	Phase 2
Ad5-nCoV	CanSino Biologics	Phase 2
BNT162	Pfizer, BioNTech	Phase 1/2

in the developing countries like India was questionable due to its cost and availability. Dexamethasone is a cheap steroid used to fight the inflammation in the moderate and severely infected patient. Based on the current progress the dexamethasone cut the mortality rate by one-third of the patients in the ventilator [55]. In the other end, the studies predicted use of the drug is safe since it carries fewer side effects based on the short exposure. On the contrary, the long term side effects of the drug are still under progress. With regard to the potential COVID vaccines, the top three candidates are Oxford-AstraZeneca, Pfizer-BioNTech & Moderna. Based on the phase 1 results, Oxford-AstraZeneca AZD1222 vaccine based on the chimpanzee ChAdOx1 adenovirus. As on July 2020, the phase II/III trials were undergoing in the countries like UK, Brazil and South Africa. Based on the outcome of phase 1 results, the vaccine generates the dual immune response to the people range between 18–55 years. AZD1222 develops the protective neutralising antibodies to target the coronavirus. In August 2020 the phase III trials to be started in India, and the vaccine available in the market as early as November with estimated cost below \$13. In the other hand, the US supported Moderna's mRNA-1273 vaccine available in the end of December with the cost of \$50–60. Moderna uses the RNA messenger to nudge the immune system to combat the virus. Pfizer (US)-BioNTech (German) BNT162b2 is on phase II/III trials, based on the results from the trials two doses of vaccines are necessary to neutralise the virus. In the major advantage of the Pfizer vaccine is its price, the expected estimated cost were \$3–4 per dose [56].

5. Conclusion

The incubation period of COVID-19 is 14 days in the host, and the possible outlier is expected to be 27 days. Besides, the average incubation period is 5.2 days, with a 95 % confidence interval level. Notable studies concluded that they could live in plastic longer than 2 days compared to copper or steel. Further, the transmission of COVID-19 from the patients to the medical personnel is vulnerable. Despite the field of general medicine, the possibility of transmission through eyes and dental practices are probable. Perhaps, washing the hands at least 5 times in the day and wearing the protective shields would reduce the transmission of COVID-19 to others, significantly. Pregnant women are more susceptible than the general population. Findings denoted no trace of intrauterine vertical transmission. Infants are not asymptomatic. None of the mothers has developed severe COVID-19 after giving birth. Further, there is no trace of the virus in breast milk until now. All infants of the infected mother were tested negative for COVID-19. In addition, lymphopenia is commonly seen in pregnant women. Early diagnosis of CoV-2 is an effective way to reduce the reproduction ratio. Although there are many ways to identify the infected person, CT- AI is an ineffective

way with high accuracy. In addition, RT-PCR can be used to detect the infection in a rapid way. Besides, IgM and IgG are also very effective, and they are coupled with the nucleic acid test.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

The authors are thankful to the Ministry of Science and Technology-Taiwan (MOST107-2113-M-037-007-MY2), and NSYSU-KMU collaboration research project (109KN007)-Taiwan for research grant supports. This work was also financially supported by the Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan from The Featured Areas Research Center Program within the framework of the 'Higher Education Sprout Project' by the Ministry of Education (MOE) in Taiwan. This study is supported partially by Kaohsiung Medical University Research Center Grant (KMU-TC108A01). The authors are thankful to Sathyabama Institute of Science and Technology-Chennai city, India, and Duy Tan University, Da Nang, Vietnam, for supporting the work.

References

- [1] C.P.E.R.E. Novel, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China, *Zhonghua liu xing bing xue za zhi= Zhonghua liuxingbingxue zazhi* 41 (2) (2020) 145.
- [2] P. Yang, X. Wang, COVID-19: a new challenge for human beings, *Cell. Mol. Immunol.* 17 (5) (2020) 555–557.
- [3] P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li, C.-L. Huang, A pneumonia outbreak associated with a new coronavirus of probable bat origin, *Nature* 579 (7798) (2020) 270–273.
- [4] W.H. Organization, Coronavirus Disease 2019 (COVID-19): Situation Report, 72, 2020.
- [5] Q. Liu, Z. Liu, J. Zhu, Y. Zhu, D. Li, Z. Gao, L. Zhou, Y. Tang, X. Zhang, J. Yang, Assessing the global tendency of COVID-19 outbreak, *MedRxiv* (2020).
- [6] F.M. Burkle, Declining public health protections within autocratic regimes: impact on global public health security, infectious disease outbreaks, epidemics, and pandemics, *Prehosp. Disaster Med.* 35 (3) (2020) 237–246.
- [7] D. Cyranski, This scientist hopes to test coronavirus drugs on animals in locked-down Wuhan, *Nature* 577 (7792) (2020) 607.
- [8] S.R. Weiss, J.L. Leibowitz, Coronavirus Pathogenesis, *Advances in Virus Research*, Elsevier, 2011, pp. 85–164.
- [9] Y. Chen, Q. Liu, D. Guo, Emerging coronaviruses: genome structure, replication, and pathogenesis, *J. Med. Virol.* 92 (4) (2020) 418–423.
- [10] N. Zhu, D. Zhang, W. Wang, China Novel Coronavirus Investigating and Research Team, A novel coronavirus from patients with pneumonia in China [published January 24, 2020], *N. Engl. J. Med.* (2019).
- [11] J. Millán-Oñate, A.J. Rodríguez-Morales, G. Camacho-Moreno, H. Mendoza-Ramírez, I.A. Rodríguez-Sabogal, C. Álvarez-Moreno, A new emerging zoonotic virus of concern: the 2019 novel Coronavirus (SARS CoV-2), *Infection* 24 (3) (2020) 187–192.
- [12] J. Cui, F. Li, Z.-L. Shi, Origin and evolution of pathogenic coronaviruses, *Nat. Rev. Microbiol.* 17 (3) (2019) 181–192.
- [13] H.A.R.N. Byrareddy, The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak, *J. Autoimmun.* (2020). Available online 26.
- [14] A.J. Kucharski, T.W. Russell, C. Diamond, Y. Liu, J. Edmunds, S. Funk, R.M. Eggo, F. Sun, M. Jit, J.D. Munday, Early dynamics of transmission and control of COVID-19: a mathematical modelling study, *Lancet Infect. Dis.* (2020).
- [15] W.-j. Guan, Z.-y. Ni, Y. Hu, W.-h. Liang, C.-q. Ou, J.-x. He, L. Liu, H. Shan, C.-l. Lei, D.S. Hui, Clinical characteristics of coronavirus disease 2019 in China, *N. Engl. J. Med.* 382 (18) (2020) 1708–1720.
- [16] T. Hosoda, M. Sakamoto, H. Shimizu, N. Okabe, SARS-CoV-2 enterocolitis with persisting to excrete the virus for approximately two weeks after recovering from diarrhea: a case report, *Infect. Control Hosp. Epidemiol.* 41 (6) (2020) 753–754.
- [17] C.-w. Lu, X.-f. Liu, Z.-f. Jia, 2019-nCoV transmission through the ocular surface must not be ignored, *Lancet (London, England)* 395 (10224) (2020) e39.
- [18] S. Beale, A.M. Johnson, M. Zambon, A.C. Hayward, E.B. Fragaszy, Hand and Respiratory Hygiene Practices and the Risk and Transmission of Human Coronavirus Infections in a UK Community Cohort, Flu Watch, Hand and Respiratory Hygiene Practices and the Risk and Transmission of Human Coronavirus Infections in a UK Community Cohort (3/8/2020), 2020.
- [19] N. Van Doremalen, T. Bushmaker, D. Morris, M. Holbrook, A. Gamble, B. Williamson, J.O. Lloyd-Smith, Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1, *N. Engl. J. Med.* (2020).

- [20] C.-b. Sun, Y.-y. Wang, G.-h. Liu, Z. Liu, Role of the eye in transmitting human coronavirus: what we know and what we do not know, *Front. Public Health* 8 (2020) 155.
- [21] X. Peng, X. Xu, Y. Li, L. Cheng, X. Zhou, B. Ren, Transmission routes of 2019-nCoV and controls in dental practice, *Int. J. Oral Sci.* 12 (1) (2020) 1–6.
- [22] A. Repici, R. Maselli, M. Colombo, R. Gabbiadini, M. Spadaccini, A. Anderloni, S. Carrara, A. Fugazza, M. Di Leo, P.A. Galtieri, Coronavirus (COVID-19) outbreak: what the department of endoscopy should know, *Gastrointest. Endosc.* (2020).
- [23] J. Ong, G.B. Cross, Y.Y. Dan, The prevention of nosocomial SARS-CoV2 transmission in endoscopy: a systematic review of recommendations within gastroenterology to identify best practice, *medRxiv* (2020).
- [24] X. Jiang, Y. Niu, X. Li, L. Li, W. Cai, Y. Chen, B. Liao, E. Wang, Is a 14-day quarantine period optimal for effectively controlling coronavirus disease 2019 (COVID-19)? *medRxiv* (2020).
- [25] Q. Bi, Y. Wu, S. Mei, C. Ye, X. Zou, Z. Zhang, X. Liu, L. Wei, S.A. Truelove, T. Zhang, Epidemiology and Transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1,286 of their close contacts, *MedRxiv* (2020).
- [26] P.-I. Lee, Y.-L. Hu, P.-Y. Chen, Y.-C. Huang, P.-R. Hsueh, Are children less susceptible to COVID-19? *J. Microbiol. Immunol. Infect.* (2020).
- [27] Q. Lu, Y. Shi, Coronavirus disease (COVID-19) and neonate: what neonatologist need to know, *J. Med. Virol.* 92 (6) (2020) 564–567.
- [28] Y. Chen, H. Peng, L. Wang, Y. Zhao, L. Zeng, H. Gao, Y. Liu, Infants born to mothers with a new coronavirus (COVID-19), *Front. Pediatr.* 8 (2020) 104.
- [29] H. Liu, L.-L. Wang, S.-J. Zhao, J. Kwak-Kim, G. Mor, A.-H. Liao, Why are pregnant women susceptible to viral infection: an immunological viewpoint? *J. Reprod. Immunol.* (2020), 103122.
- [30] Y. Li, R. Zhao, S. Zheng, X. Chen, J. Wang, X. Sheng, J. Zhou, H. Cai, Q. Fang, F. Yu, Lack of vertical transmission of severe acute respiratory syndrome coronavirus 2, *China* (2020).
- [31] H. Chen, et al., Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records, *Lancet* (2020), [https://doi.org/10.1016/S0140-6736\(20\)30360-3](https://doi.org/10.1016/S0140-6736(20)30360-3).
- [32] Y. Sugishita, J. Kurita, T. Sugawara, Y. Ohkusa, Preliminary evaluation of voluntary event cancellation as a countermeasure against the COVID-19 outbreak in Japan as of 11 March, 2020, *medRxiv* (2020).
- [33] X. Jia, P. Zhang, Y. Tian, J. Wang, H. Zeng, J. Wang, L. Jiao, Z. Chen, L. Zhang, H. He, Clinical significance of IgM and IgG test for diagnosis of highly suspected COVID-19 infection, *medRxiv* (2020).
- [34] P. Zhang, Q. Gao, T. Wang, Y. Ke, F. Mo, R. Jia, W. Liu, L. Liu, S. Zheng, Y. Liu, Evaluation of recombinant nucleocapsid and spike proteins for serological diagnosis of novel coronavirus disease 2019 (COVID-19), *MedRxiv* (2020).
- [35] R. Konrad, U. Eberle, A. Dangel, B. Treis, A. Berger, K. Bengs, V. Fingerle, B. Liebl, N. Ackermann, A. Sing, Rapid establishment of laboratory diagnostics for the novel coronavirus SARS-CoV-2 in Bavaria, Germany, February 2020, *Eurosurveillance* 25 (9) (2020), 2000173.
- [36] K.G. Andersen, A. Rambaut, W.I. Lipkin, E.C. Holmes, R.F. Garry, The proximal origin of SARS-CoV-2, *Nat. Med.* 26 (4) (2020) 450–452.
- [37] L. Fan, D. Li, H. Xue, L. Zhang, Z. Liu, B. Zhang, L. Zhang, W. Yang, B. Xie, X. Duan, Progress and prospect on imaging diagnosis of COVID-19, *Chin. J. Acad. Radiol.* (2020) 1–10.
- [38] H.S. Maghddid, K.Z. Ghafoor, A.S. Sadiq, K. Curran, K. Rabie, A novel ai-enabled framework to diagnose coronavirus covid 19 using smartphone embedded sensors: design study, *arXiv preprint arXiv:2003.07434* (2020).
- [39] Y. Song, S. Zheng, L. Li, X. Zhang, X. Zhang, Z. Huang, J. Chen, H. Zhao, Y. Jie, R. Wang, Deep learning enables accurate diagnosis of novel coronavirus (COVID-19) with CT images, *medRxiv* (2020).
- [40] T. Ai, Z. Yang, H. Hou, C. Zhan, C. Chen, W. Lv, Q. Tao, Z. Sun, L. Xia, Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases [published online ahead of print February 26, 2020], *Radiology* 10 (2020).
- [41] Z. Cheng, Y. Lu, Q. Cao, L. Qin, Z. Pan, F. Yan, W. Yang, Clinical features and chest CT manifestations of coronavirus disease 2019 (COVID-19) in a single-center study in Shanghai, China, *Am. J. Roentgenol.* (2020) 1–6.
- [42] X. Xie, Z. Zhong, W. Zhao, C. Zheng, F. Wang, J. Liu, Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing, *Radiology* (2020), 200343.
- [43] M. Chung, A. Bernheim, X. Mei, N. Zhang, M. Huang, X. Zeng, J. Cui, W. Xu, Y. Yang, Z.A. Fayad, A. Jacobi, K. Li, S. Li, H. Shan, CT imaging features of 2019 novel coronavirus (2019-nCoV), *Radiology.* (2020), <https://doi.org/10.1148/radiol.2020200230>.
- [44] V.M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K. Chu, T. Bleicker, S. Brünink, J. Schneider, M.L. Schmidt, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, *Eurosurveillance* 25 (3) (2020), 2000045.
- [45] W. Han, B. Quan, Y. Guo, J. Zhang, Y. Lu, G. Feng, Q. Wu, F. Fang, L. Cheng, N. Jiao, The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019, *J. Med. Virol.* 92 (5) (2020) 461–463.
- [46] E. Bischof, G. Chen, M.T. Ferretti, Understanding COVID-19 new diagnostic guidelines—a message of reassurance from an internal medicine doctor in Shanghai, *Swiss Med.* 150 (0910) (2020).
- [47] W.H. Organization, Laboratory Testing for Coronavirus Disease (COVID-19) in Suspected Human Cases: Interim Guidance, 19 March 2020, *World Health Organization*, 2020.
- [48] Y. Hirotsu, H. Mochizuki, M. Omata, Double-quencher probes improved the detection sensitivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by one-step RT-PCR, *medRxiv* (2020).
- [49] A.M. Casto, M.-L. Huang, A. Nalla, G.A. Perchetti, R. Sampoleo, L. Shrestha, Y. Wei, H. Zhu, A.L. Greninger, K.R. Jerome, Comparative performance of SARS-CoV-2 detection assays using seven different Primer/Probe sets and one assay kit, *medRxiv* (2020).
- [50] M. Fadel, J. Salomon, A. Descatha, Coronavirus outbreak: the role of companies in preparedness and responses, *Lancet Public Health* 5 (4) (2020) e193.
- [51] Wei Lyu, George L. Wehby, Community use of face masks and COVID-19: evidence from a natural experiment of state mandates in the US: study examines impact on COVID-19 growth rates associated with state government mandates requiring face mask use in public, *Health Aff.* (2020) 10–1377.
- [52] Reza Aminnejad, Alireza Salimi, Mohammad Saeidi, Lidocaine during intubation and extubation in patients with coronavirus disease (COVID-19), *Canad. J. Anesthesia* (2020), <https://doi.org/10.1007/s12630-020-01627-2>.
- [53] L. Shaffer, 15 drugs being tested to treat COVID-19 and how they would work, *Nat. Med.* (2020). <https://www.nature.com/articles/d41591-020-00019-9>.
- [54] John H. Beigel, Kay M. Tomashek, Lori E. Dodd, Aneesh K. Mehta, Barry S. Zingman, Andre C. Kalil, Elizabeth Hohmann, et al., Remdesivir for the treatment of Covid-19—preliminary report, *N. Engl. J. Med.* (2020), <https://doi.org/10.1056/NEJMc2022236>.
- [55] Chang Moon, Dexamethasone to the Rescue, 2020, p. 1, <https://doi.org/10.1038/s41577-020-0394-2>.
- [56] COVID-19 vaccine tracker RAPS, 2020 n.d. <https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker> (accessed July 30, 2020).